Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lou Fintor

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of the National Cancer Institute|March 7, 2002
Direct-to-consumer marketing: how has it fared?Lou Fintor
Journal of the National Cancer Institute|May 16, 2002
Health agencies adopt new disease classification codesLou Fintor
Journal of the National Cancer Institute|August 7, 2003
Breast cancer group targets 'shareholder activism' at AvonLou Fintor
Journal of the National Cancer Institute|May 16, 2002
New uniform population standard better reflects U.S. cancer burdenLou Fintor
Journal of the National Cancer Institute|March 7, 2002
AstraZeneca reprimanded for nolvadex advertisementLou Fintor
Journal of the National Cancer Institute|July 4, 2002
Vagaries of research publishing again under the microscopeLou Fintor
Journal of the National Cancer Institute|October 3, 2002
Increase in drug tampering reports sparks new security considerationsLou Fintor
American Journal of Obstetrics and Gynecology|April 23, 2002
Factor V Leiden mutation and preeclampsiaJános Rigó, Bálint Nagy, Lou Fintor
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of the National Cancer Institute|March 7, 2002
Direct-to-consumer marketing: how has it fared?Lou Fintor
Journal of the National Cancer Institute|May 16, 2002
Health agencies adopt new disease classification codesLou Fintor
Journal of the National Cancer Institute|August 7, 2003
Breast cancer group targets 'shareholder activism' at AvonLou Fintor
Journal of the National Cancer Institute|May 16, 2002
New uniform population standard better reflects U.S. cancer burdenLou Fintor
Journal of the National Cancer Institute|March 7, 2002
AstraZeneca reprimanded for nolvadex advertisementLou Fintor
Journal of the National Cancer Institute|July 4, 2002
Vagaries of research publishing again under the microscopeLou Fintor
Journal of the National Cancer Institute|October 3, 2002
Increase in drug tampering reports sparks new security considerationsLou Fintor
American Journal of Obstetrics and Gynecology|April 23, 2002
Factor V Leiden mutation and preeclampsiaJános Rigó, Bálint Nagy, Lou Fintor
Pageof 1